Prevention of Mantle Lymphoma Tumor Establishment by Routing Transferrin Receptor toward Lysosomal Compartments
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Mantle cell lymphoma (MCL) is one of the most frequent of the newly recognized non-Hodgkin's lymphomas. The major problem of MCL therapy is the occurrence of relapse and subsequent resistance to chemotherapy and immunotherapy in virtually all cases. Here, we show that one injection of anti-human transferrin receptor (TfR) monoclonal antibody A24 totally prevented xenografted MCL tumor establishment in nude mice. It also delayed and inhibited tumor progression of established tumors, prolonging mice survival. In vitro, A24 induced up to 85% reduction of MCL cell proliferation (IC50 = 3.75 nmol/L) independently of antibody aggregation, complement-dependent or antibody-dependent cell-mediated cytotoxicity. A24 induced MCL cell apoptosis through caspase-3 and caspase-9 activation, either alone or synergistically with chemotherapeutic agents. A24 induced TfR endocytosis via the clathrin adaptor protein-2 complex pathway followed by transport to lysosomal compartments. Therefore, A24-based therapies alone or in association with classic chemotherapies could provide a new alternative strategy against MCL, particularly in relapsing cases. [Cancer Res 2007;67(3):1145–54]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Differential requirements for AP-2 in clathrin-mediated endocytosis
Conner, S. D., & Schmid, S. L. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200304069 · Cited by 196
Moura, I. C. (2004) · Blood · doi:10.1182/blood-2003-07-2440 · Cited by 114
Cited by
Lim, J. C. W., Chan, T. K., Ng, D. S., Sagineedu, S. R., Stanslas, J., & Wong, W. F. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05633.x · Cited by 268
Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents
Candelaria, P. V., Leoh, L. S., Penichet, M. L., & Daniels-Wells, T. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.607692 · Cited by 268
Callens, C., Coulon, S., Naudin, J., Radford-Weiss, I., Boissel, N., Raffoux, E., Wang, P. H. M., Agarwal, S., Tamouza, H., Paubelle, E., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091488 · Cited by 197
“A24 specifically binds to TfR1high cells, competes with ironloaded transferrin (FeTf) for receptor binding, and impairs receptor recycling, thereby drastically impairing iron uptake (Moura et al., 2004; Lepelletier et al., 2007; Callens et al., 2008).”
BackgroundMethodInfluentialSelf-citationThe role of iron in tumour cell proliferation
Steegmann-Olmedillas, J. L. (2011) · Clinical and Translational Oncology · doi:10.1007/s12094-011-0621-1 · Cited by 84
“For example, the antibody mAb A24 has already proved its activity in animal models [ 41 ] and adult T-cell leukaemia-lymphoma [42].”
BackgroundLi, W., Xu, L.-H., Forssell, C., Sullivan, J. L., & Yuan, X.-M. (2008) · Experimental Biology and Medicine · doi:10.3181/0711-rm-320 · Cited by 69
“TfRs have been explored as molecular targets for imaging and treatment of rapid growth tumors (36, 37).”
Background
Metadata
- Authors
- Lepelletier, Y., Camara-Clayette, V., Jin, H., Hermant, A., Coulon, S., Dussiot, M., Arcos-Fajardo, M., Baude, C., Canionni, D., Delarue, R., Brousse, N., Benaroch, P., Benhamou, M., Ribrag, V., Monteiro, R. C., Moura, I. C., & Hermine, O.
- Venue
- Cancer Research
- Published
- 2007-02-01
- Volume
- 67
- Issue
- 3
- Pages
- 1145-1154
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2073055972
- Cited by
- 37
- References
- 2
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of Mantle Lymphoma Tumor Establishment by Routing Transferrin Receptor toward Lysosomal Compartments. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-1962
- The paper
- Lepelletier, Y., Camara-Clayette, V., Jin, H., Hermant, A., Coulon, S., Dussiot, M., Arcos-Fajardo, M., Baude, C., Canionni, D., Delarue, R., Brousse, N., Benaroch, P., Benhamou, M., Ribrag, V., Monteiro, R. C., Moura, I. C., & Hermine, O. (2007). Prevention of Mantle Lymphoma Tumor Establishment by Routing Transferrin Receptor toward Lysosomal Compartments. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-1962
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.